Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma. 2020

E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
P.A. Hertsen Moscow Oncology Research Center - Branch of Federal State Budgetary Institution National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Moscow, Russia. Electronic address: derkul23@yandex.ru.

Topical 5-aminolevulinic acid-mediated photodynamic therapy is an established approach for the treatment of basal cell carcinoma. This study with 5- aminolevulinic acid drug Levulon was conducted in patients with superficial skin basal cell carcinoma. The study included 82 patients with overall number of tumor foci of 119. Tumor sites were as follows: head and neck, trunk, extremities.A total of two photodynamic therapy sessions, four weeks apart were performed using a laser with a wavelength of 630 nm and energy density of 350 J/cm2. A complete response was recorded in 77 patients (114 foci) with an excellent cosmetic result. According to the analysis of survival in the group of patients with a complete response, the overall RFS was as follows: 1-year rate - 92.1 %, 3-year - 88.3 %. Photodynamic therapy with topical Levulon in patients with superficial BCC of the skin was effective and safe.

UI MeSH Term Description Entries
D010778 Photochemotherapy Therapy using oral or topical photosensitizing agents with subsequent exposure to light. Blue Light Photodynamic Therapy,Photodynamic Therapy,Red Light PDT,Red Light Photodynamic Therapy,Therapy, Photodynamic,Light PDT, Red,PDT, Red Light,Photochemotherapies,Photodynamic Therapies,Therapies, Photodynamic
D002280 Carcinoma, Basal Cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471) Carcinoma, Basal Cell, Pigmented,Epithelioma, Basal Cell,Rodent Ulcer,Ulcer, Rodent,Basal Cell Carcinoma,Basal Cell Carcinomas,Basal Cell Epithelioma,Basal Cell Epitheliomas,Carcinomas, Basal Cell,Epitheliomas, Basal Cell,Rodent Ulcers,Ulcers, Rodent
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000622 Aminolevulinic Acid A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS. 5-Amino Levulinic Acid,5-Aminolaevulinate,5-Aminolevulinate,Aminolevulinic Acid Hydrochloride,Delta-Aminolevulinic Acid,Levulan,5 Amino Levulinic Acid,5 Aminolaevulinate,5 Aminolevulinate,Acid Hydrochloride, Aminolevulinic,Acid, 5-Amino Levulinic,Acid, Aminolevulinic,Acid, Delta-Aminolevulinic,Delta Aminolevulinic Acid,Hydrochloride, Aminolevulinic Acid,Levulinic Acid, 5-Amino
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D017319 Photosensitizing Agents Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. Photosensitizer,Photosensitizers,Photosensitizing Agent,Photosensitizing Effect,Photosensitizing Effects,Agent, Photosensitizing,Agents, Photosensitizing,Effect, Photosensitizing,Effects, Photosensitizing

Related Publications

E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
January 2000, Acta oncologica (Stockholm, Sweden),
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
January 2004, Acta dermatovenerologica Croatica : ADC,
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
January 1994, Photochemistry and photobiology,
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
August 2013, Journal of the European Academy of Dermatology and Venereology : JEADV,
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
January 2000, The Journal of dermatology,
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
April 2005, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
November 2012, Annals of dermatology,
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
January 1998, Dermatology (Basel, Switzerland),
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
September 2000, Archives of dermatology,
E Filonenko, and A Kaprin, and A Urlova, and N Grigorievykh, and V Ivanova-Radkevich
December 2019, Photodiagnosis and photodynamic therapy,
Copied contents to your clipboard!